The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations.
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
16 Nov 2023
16 Nov 2023
Historique:
accepted:
26
10
2023
medline:
17
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
aheadofprint
Résumé
Over the past 2 years, several drugs have been approved for coronavirus disease 2019 (COVID-19) treatment, but their safety during pregnancy remains poorly understood. This study aims to assess the relative risk of obstetric, neonatal, and infant outcomes associated with the use of drugs specifically indicated for the treatment of COVID-19 compared with other drug treatment strategies. The purpose of this article is to present elements of the study protocol. The COVID-19 International Drug Pregnancy Registry (COVID-PR) is a noninterventional, postmarketing cohort study. Pregnant women receiving treatment with monoclonal antibodies (mAbs) or antiviral drugs for mild, moderate, or severe COVID-19 are matched 1:1 with pregnant women not receiving these study-specific drugs, based on calendar time, country, gestational age at enrollment, and COVID-19 severity. Participants complete online questionnaires at enrollment, during pregnancy, and for 12 months after delivery of liveborn infants. The study began enrolling participants on 1 December 2021 and is set to span 5 years for each drug of interest. The COVID-PR is designed to evaluate the safety profile of each studied drug. Additionally, it may allow for an analysis of the effects of COVID-19 drug exposure during relevant gestational periods on specific neonatal outcomes. Although the sample size will be too small to detect associations with rare outcomes, the study has the potential to generate hypotheses for future research. Ultimately, these data can provide valuable insights for evidence-based decisions about COVID-19 treatment during pregnancy. ClinicalTrials.gov: NCT05013632. EU PAS EUPAS42517.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Over the past 2 years, several drugs have been approved for coronavirus disease 2019 (COVID-19) treatment, but their safety during pregnancy remains poorly understood. This study aims to assess the relative risk of obstetric, neonatal, and infant outcomes associated with the use of drugs specifically indicated for the treatment of COVID-19 compared with other drug treatment strategies. The purpose of this article is to present elements of the study protocol.
METHODS
METHODS
The COVID-19 International Drug Pregnancy Registry (COVID-PR) is a noninterventional, postmarketing cohort study. Pregnant women receiving treatment with monoclonal antibodies (mAbs) or antiviral drugs for mild, moderate, or severe COVID-19 are matched 1:1 with pregnant women not receiving these study-specific drugs, based on calendar time, country, gestational age at enrollment, and COVID-19 severity. Participants complete online questionnaires at enrollment, during pregnancy, and for 12 months after delivery of liveborn infants. The study began enrolling participants on 1 December 2021 and is set to span 5 years for each drug of interest.
DISCUSSION
CONCLUSIONS
The COVID-PR is designed to evaluate the safety profile of each studied drug. Additionally, it may allow for an analysis of the effects of COVID-19 drug exposure during relevant gestational periods on specific neonatal outcomes. Although the sample size will be too small to detect associations with rare outcomes, the study has the potential to generate hypotheses for future research. Ultimately, these data can provide valuable insights for evidence-based decisions about COVID-19 treatment during pregnancy.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov: NCT05013632. EU PAS EUPAS42517.
Identifiants
pubmed: 37973784
doi: 10.1007/s40264-023-01377-2
pii: 10.1007/s40264-023-01377-2
doi:
Banques de données
ClinicalTrials.gov
['NCT05013632']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Adam S, Pheiffer C, Dias S, Hlongwane T, Vannevel V, Soma-Pillay P, et al. Coronavirus and pregnancy: the challenges of the 21(st) century: a review. Front Microbiol. 2022;13: 923546.
doi: 10.3389/fmicb.2022.923546
pubmed: 35910606
pmcid: 9326040
Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol. 2022;226(2):177–86.
doi: 10.1016/j.ajog.2021.08.054
pubmed: 34534497
Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021;175(8):817–26.
doi: 10.1001/jamapediatrics.2021.1050
pubmed: 33885740
Villar J, Soto CCP, Gunier RB, Ariff S, Craik R, Cavoretto PI, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet. 2023;401(10375):447–57.
doi: 10.1016/S0140-6736(22)02467-9
pubmed: 36669520
pmcid: 9910845
Ellington S, Strid P, Tong VT, Woodworth K, Galang RR, Zambrano LD, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):769–75.
doi: 10.15585/mmwr.mm6925a1
pubmed: 32584795
pmcid: 7316319
Collin J, Bystrom E, Carnahan A, Ahrne M. Public Health Agency of Sweden’s brief report: pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden. Acta Obstet Gynecol Scand. 2020;99(7):819–22.
doi: 10.1111/aogs.13901
pubmed: 32386441
Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370: m3320.
doi: 10.1136/bmj.m3320
pubmed: 32873575
Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nat Rev Immunol. 2022;22(5):277–82.
doi: 10.1038/s41577-022-00703-6
pubmed: 35304596
pmcid: 8931577
Regulatory Affairs Professionals Society. COVID-19 therapeutics tracker 2022. Available from https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker . Accessed August 16, 2022.
Pidiyar V, Kumraj G, Ahmed K, Ahmed S, Shah S, Majumder P, et al. COVID-19 management landscape: a need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries. Vaccine. 2022;40:5302–12.
doi: 10.1016/j.vaccine.2022.05.065
pubmed: 35914959
pmcid: 9148927
World Health Organization (WHO). Therapeutics and COVID-19: living guideline 2023 [v13.1]. Available from: https://app.magicapp.org/#/guideline/nBkO1E . Accessed April 5, 2023.
U.S. National Institutes of Health. Covid-19 treatment guidelines: clinical management of adults 2023. [updated May 2, 2023]. Available from https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/clinical-management-of-adults-summary/ . Accessed June 19, 2023.
Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, et al. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J Biomed Sci. 2022;29(1):68.
doi: 10.1186/s12929-022-00852-9
pubmed: 36096815
pmcid: 9465653
U.S. Food and Drug Administration. Fact sheet for healthcare providers: Emergency use authorization for Lagevrio (molnupiravir) capsules 2022. Available from https://www.fda.gov/media/155054/download . Accessed: August 17, 2022.
Altafim ERP, McCoy DC, Brentani A, Escobar AMU, Grisi S, Fink G. Measuring early childhood development in Brazil: validation of the caregiver reported early development instruments (CREDI). J Pediatr (Rio J). 2020;96(1):66–75.
doi: 10.1016/j.jped.2018.07.008
pubmed: 30102876
Li Y, Tang L, Bai Y, Zhao S, Shi Y. Reliability and validity of the caregiver reported early development instruments (CREDI) in impoverished regions of China. BMC Pediatr. 2020;20(1):475.
doi: 10.1186/s12887-020-02367-4
pubmed: 33046019
pmcid: 7549226
U.S. Centers for Disease Control and Prevention. Birth defects research and tracking 2021 [updated July 21, 2021]. Available from https://www.cdc.gov/ncbddd/birthdefects/data.html . Accessed August 9, 2022.
U.S. Food and Drug Administration. 2023. Available from https://www.fda.gov . Accessed June 19, 2023.
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). 2023. Available from: https://www.encepp.eu . Accessed June 19, 2023.
U.S. National Library of Medicine. ClinicalTrials.gov 2023. Available from: https://clinicaltrials.gov/ . Accessed June 19, 2023.
Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121–30.
doi: 10.2307/2531248
pubmed: 3719049
European Commission. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). OJ2016. p. 1–88.
International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals 2019. Available from: http://www.icmje.org/recommendations/ . Accessed July 27, 2022.
Margulis AV, Mittleman MA, Glynn RJ, Holmes LB, Hernandez-Diaz S. Effects of gestational age at enrollment in pregnancy exposure registries. Pharmacoepidemiol Drug Saf. 2015;24(4):343–52.
doi: 10.1002/pds.3731
pubmed: 25702683
McCoy DC, Sudfeld CR, Bellinger DC, Muhihi A, Ashery G, Weary TE, et al. Development and validation of an early childhood development scale for use in low-resourced settings. Popul Health Metr. 2017;15(1):3.
doi: 10.1186/s12963-017-0122-8
pubmed: 28183307
pmcid: 5301363